urea has been researched along with Ovarian Neoplasms in 22 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In 14 out of the 20 pts (70 %) the recurrence occurred during chemotherapy or within 6 months after the end of the chemotherapy." | 2.71 | Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). ( Chatzigeorgiou, K; Chatzigeorgiou, N; Chrysafis, G; Dimasis, A; Economou, S; Lyratzopoulos, N; Manolas, K; Minopoulos, G; Setzis, K; Zafiriou, G, 2003) |
| "Adriamycin (doxorubicin, Adriblastin) and cis-diammine-dichloro-platinum (II) (DDP, NSC 119 875) were used in the treatment of 18 patients with ovarian carcinoma, usually after intensive pre-treatment, both in a dosage of 50 mg/m2 once every 4 weeks." | 2.64 | [Combination of adriamycin and cis-diammine-dichloro-platinum (II) in the treatment of advanced, therapy-resistant, ovarian carcinoma (author's transl)]. ( Brunner, KW; Cavalli, F; Sonntag, RW; Stoller, U; Tschopp, L, 1978) |
| " Selectivity of protection by WR2721 is probably due to the preferential formation and uptake of the thiol metabolite 2-(3-aminopropylamino)ethanethiol (WR1065), which can inactivate toxic platinum-species inside the cell." | 1.28 | Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. ( Boven, E; Holwerda, U; Pinedo, HM; Treskes, M; van der Vijgh, WJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (45.45) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 4 (18.18) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Gnanasekaran, KK | 1 |
| Pouland, T | 2 |
| Bunce, RA | 2 |
| Darrell Berlin, K | 1 |
| Abuskhuna, S | 1 |
| Bhandari, D | 2 |
| Mashayekhi, M | 2 |
| Zhou, DH | 1 |
| Benbrook, DM | 3 |
| Meng, Y | 1 |
| Chen, CW | 1 |
| Yung, MMH | 1 |
| Sun, W | 1 |
| Sun, J | 1 |
| Li, Z | 2 |
| Li, J | 1 |
| Zhou, W | 1 |
| Liu, SS | 1 |
| Cheung, ANY | 1 |
| Ngan, HYS | 1 |
| Braisted, JC | 1 |
| Kai, Y | 1 |
| Peng, W | 1 |
| Tzatsos, A | 1 |
| Li, Y | 1 |
| Dai, Z | 1 |
| Zheng, W | 1 |
| Chan, DW | 1 |
| Zhu, W | 1 |
| Watts, FM | 1 |
| Berlin, KD | 2 |
| Zhou, D | 1 |
| Itamochi, H | 1 |
| Nishimura, M | 1 |
| Oumi, N | 1 |
| Kato, M | 1 |
| Oishi, T | 1 |
| Shimada, M | 1 |
| Sato, S | 2 |
| Naniwa, J | 1 |
| Kudoh, A | 1 |
| Kigawa, J | 1 |
| Harada, T | 1 |
| Bryant, C | 1 |
| Rawlinson, R | 1 |
| Massey, AJ | 1 |
| Chatzigeorgiou, K | 1 |
| Economou, S | 1 |
| Chrysafis, G | 1 |
| Dimasis, A | 1 |
| Zafiriou, G | 1 |
| Setzis, K | 1 |
| Lyratzopoulos, N | 1 |
| Minopoulos, G | 1 |
| Manolas, K | 1 |
| Chatzigeorgiou, N | 1 |
| Liu, S | 1 |
| Brown, CW | 1 |
| Dhar, A | 1 |
| Guruswamy, S | 1 |
| Brown, D | 1 |
| Gardner, GJ | 1 |
| Birrer, MJ | 1 |
| Ferriss, JB | 1 |
| Brown, JJ | 1 |
| Fraser, R | 1 |
| Lever, AF | 1 |
| Robertson, JI | 1 |
| Hightower, RD | 1 |
| Sevin, BU | 1 |
| Perras, J | 1 |
| Nguyen, H | 1 |
| Angioli, R | 1 |
| Untch, M | 1 |
| Averette, H | 1 |
| Andersson, H | 1 |
| Lindegren, S | 1 |
| Bäck, T | 1 |
| Jacobsson, L | 1 |
| Leser, G | 1 |
| Horvath, G | 1 |
| Zalutsky, MR | 1 |
| Xu, FJ | 1 |
| Yu, Y | 1 |
| Foulon, CF | 1 |
| Zhao, XG | 1 |
| Slade, SK | 1 |
| Affleck, DJ | 1 |
| Bast, RC | 1 |
| Visser, GW | 1 |
| Klok, RP | 1 |
| Gebbinck, JW | 1 |
| ter Linden, T | 1 |
| van Dongen, GA | 1 |
| Molthoff, CF | 1 |
| Gerber, AC | 1 |
| Kozdrowski, I | 1 |
| Wyss, SR | 1 |
| Berger, EG | 1 |
| Cavalli, F | 1 |
| Stoller, U | 1 |
| Tschopp, L | 1 |
| Sonntag, RW | 1 |
| Brunner, KW | 1 |
| Wiltshaw, E | 1 |
| Kroner, T | 1 |
| Treskes, M | 1 |
| Boven, E | 1 |
| Holwerda, U | 1 |
| Pinedo, HM | 1 |
| van der Vijgh, WJ | 1 |
| Qian, HN | 1 |
| Feng, J | 1 |
| Fu, TY | 1 |
| Marsh, JC | 1 |
| DeConti, RC | 1 |
| Hubbard, SP | 1 |
| Rustia, M | 1 |
| McGowan, L | 1 |
| Davis, RH | 1 |
| Bunnag, B | 1 |
| Ivankovic, S | 1 |
| Black, JA | 1 |
| Chan, GF | 1 |
| Hew, CL | 1 |
| Dixon, GH | 1 |
1 review available for urea and Ovarian Neoplasms
| Article | Year |
|---|---|
Primary hyperaldosteronism.
Topics: Adenoma; Adolescent; Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adrenal Glands; Adult; Aged; | 1981 |
4 trials available for urea and Ovarian Neoplasms
| Article | Year |
|---|---|
Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP).
Topics: Disease-Free Survival; Female; Humans; Hyperthermia, Induced; Intraoperative Care; Intraoperative Pe | 2003 |
[Combination of adriamycin and cis-diammine-dichloro-platinum (II) in the treatment of advanced, therapy-resistant, ovarian carcinoma (author's transl)].
Topics: Adult; Cisplatin; Clinical Trials as Topic; Creatinine; Doxorubicin; Drug Evaluation; Drug Resistanc | 1978 |
Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Blood Platelets; Cisplatin; Drug Administration | 1976 |
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents; | 1971 |
17 other studies available for urea and Ovarian Neoplasms
| Article | Year |
|---|---|
Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Chromans; Female; Humans | 2020 |
DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Protein | 2018 |
Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromans; Female; HSP70 Heat-Shock Proteins; Humans; Molecu | 2018 |
Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resist | 2014 |
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Topics: Benzodiazepinones; Biomarkers, Tumor; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Deoxycytidin | 2014 |
Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Computer Simulation; Drug Screeni | 2004 |
In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzofurans; Cisplatin; Cyclohexanecarboxylic Acids; | 1993 |
Biokinetics of the monoclonal antibodies MOv 18, OV 185 and OV 197 labelled with 125I according to the m-MeATE method or the Iodogen method in nude mice with ovarian cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Benzoates; Female; Humans; Indicators and Reagents; Iodine Radioiso | 1999 |
Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution.
Topics: Animals; Antibodies, Monoclonal; Cellobiose; Female; Humans; Immunoconjugates; Iodine Radioisotopes; | 1999 |
Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
Topics: Animals; Antibodies, Monoclonal; Carrier Proteins; Female; Folate Receptors, GPI-Anchored; Indicator | 2001 |
The charge heterogeneity of soluble human galactosyltransferases isolated from milk, amniotic fluid and malignant ascites.
Topics: Amino Acids; Amniotic Fluid; Ascites; Female; Galactosyltransferases; Humans; Hydrogen-Ion Concentra | 1979 |
Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Topics: Amifostine; Animals; Cisplatin; Drug Administration Schedule; Female; Kidney; Liver; Male; Mannitol; | 1992 |
The study of antibodies and antigens dissociated from the immune complexes extracted from ovarian carcinoma ascitic fluid.
Topics: Adenocarcinoma; Antibodies, Neoplasm; Antigen-Antibody Complex; Antigens, Neoplasm; Ascitic Fluid; C | 1985 |
Multiple carcinogenic effects of the ethylnitrosourea precursors ethylurea and sodium nitrite in hamsters.
Topics: Age Factors; Animals; Carcinogens; Carcinoma, Squamous Cell; Cricetinae; Female; Liver Neoplasms; Ma | 1974 |
The biochemical diagnosis of ovarian cancer.
Topics: Adenocarcinoma; Ascitic Fluid; Aspartate Aminotransferases; Bilirubin; Calcium; Cholesterol; Cystade | 1973 |
[Induction of genital cancer in pregnant rats].
Topics: Abdominal Neoplasms; Adenocarcinoma; Animals; Carcinoma, Papillary; Carcinoma, Squamous Cell; Female | 1969 |
Gene action in the human haptoglobins. 3. Isolation of the alpha-chains as single gene products. Isolation, molecular weight, and amino acid composition of alpha and beta chains.
Topics: Acetamides; Alkylation; Amino Acids; Anhydrides; Ascitic Fluid; Carcinoma; Chemical Phenomena; Chemi | 1970 |